ADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

ADAR1 Capital Management LLC reduced its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 79.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,067 shares of the company’s stock after selling 255,118 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Vir Biotechnology were worth $470,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in VIR. Rhumbline Advisers boosted its stake in Vir Biotechnology by 0.5% during the fourth quarter. Rhumbline Advisers now owns 236,681 shares of the company’s stock worth $1,737,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,999 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Vir Biotechnology by 10.7% in the fourth quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company’s stock valued at $194,000 after acquiring an additional 2,556 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vir Biotechnology by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company’s stock valued at $214,000 after acquiring an additional 2,922 shares in the last quarter. Finally, KBC Group NV raised its position in shares of Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after purchasing an additional 5,177 shares during the period. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Trading Down 6.4 %

Shares of NASDAQ:VIR opened at $5.58 on Monday. The stock has a market capitalization of $765.26 million, a P/E ratio of -1.42 and a beta of 1.14. Vir Biotechnology, Inc. has a 12-month low of $5.36 and a 12-month high of $14.45. The stock’s 50-day moving average price is $8.36 and its 200-day moving average price is $8.29.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.09. The company had revenue of $12.37 million for the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analysts Set New Price Targets

VIR has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. Leerink Partners boosted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 27th. Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Finally, Barclays increased their target price on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.67.

Insider Activity at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of Vir Biotechnology stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,571 shares of company stock worth $800,744 over the last ninety days. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).